Response to Letter to the Editor on “Early benefit assessment of new drugs in Germany – Results from 2011 to 2012” [Health Policy 116(2–3) (2014) 147

登录注册会员服务联系我们

Response to Letter to the Editor on “Early benefit assessment of new drugs in Germany – Results from 2011 to 2012” [Health Policy 116(2–3) (2014) 147–153]

Published:2014-11 Issue:2 Volume:118 Page:272
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Hörn Helmut,Nink Katrin,McGauran Natalie,Wieseler Beate

Publisher

Elsevier BV

Subject

Health Policy

Reference2 articles.

1. SGB V Sozialgesetzbuch: Gesetzliche Krankenversicherung; § 35a SGB V Bewertung des Nutzens von Arzneimitteln mit neuen Wirkstoffen,2014

2. Verordnung über die Nutzenbewertung von Arzneimitteln nach § 35a Absatz 1 SGB V für Erstattungsvereinbarungen nach § 130b SGB V (Arzneimittel-Nutzenbewertungsverordnung – AM-NutzenV);Bundesminister für Gesundheit;Bundesgesetzblatt Teil,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disentangling organizational levers and economic benefits in transitional care programs: a systematic review and configurational analysis;BMC Health Services Research;2024-01-09

2. Disentangling organizational and economic levers in transitional care programs: A systematic review and configurational analysis;2023-09-07

3. Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA;Expert Review of Pharmacoeconomics & Outcomes Research;2020-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP